| Literature DB >> 30301135 |
Christian Butter1,2, Jessica Groß3,4, Anja Haase-Fielitz5,6, Helen Sims7, Cornelia Deutsch8, Peter Bramlage9, Michael Neuss10,11.
Abstract
The benefit of rehabilitation in elderly patients undergoing transcatheter aortic valve implantation (TAVI) for treatment of severe aortic stenosis is unknown. The impact of declining rehabilitation programs on mortality has also not been described. In a longitudinal cohort study of 1056 patients undergoing elective TAVI between 2008 and 2016, logistic regression analysis was used to assess the relationship between treatment modality and outcome according to whether or not patients participated in a three-week rehabilitation program after TAVI. Subgroup analyses included patient outcome separated according to cardiac, geriatric, or no rehabilitation. A total of 1017 patients survived until hospital discharge (96.3%) and were offered rehabilitation, 366 patients (36.0%) declined to undergo rehabilitation, with the remaining patients undergoing either cardiac (n = 435; 42.8%) or geriatric rehabilitation (n = 216; 21.2%). Mortality at six months was lower for patients receiving rehabilitation compared with those who had not (adjusted odds ratio (OR): 0.49; 95% confidence interval (confidence interval [CI]: 0.25⁻0.94; p = 0.032). Sub-analysis showed the benefit of cardiac (adjusted OR: 0.31; 95% CI 0.14⁻0.71, p = 0.006), but not geriatric rehabilitation (adjusted OR 0.83; 95% CI 0.37⁻1.85, p = 0.65). A program of rehabilitation after TAVI has the potential to reduce mortality. Future studies should focus on health-orientated behavior and identifying risk factors for declining rehabilitation programs.Entities:
Keywords: TAVI; aortic stenosis; cardiac rehabilitation; heart valve; mortality
Year: 2018 PMID: 30301135 PMCID: PMC6210128 DOI: 10.3390/jcm7100326
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Patient flow through the study. TAVI, transcatheter aortic valve implantation; FU, follow-up.
Patient characteristics at baseline.
| Rehabilitation ( | No Rehabilitation ( | ||
|---|---|---|---|
| Age (years) | 80.7 ± 6.0 | 80.1 ± 6.1 | 0.107 |
| Male sex | 290/651 (44.5) | 177/366 (48.4) | 0.241 |
| Body mass index (kg/m2) | 27.4 ± 5.3 | 28.3 ± 6.2 | 0.017 |
| Diabetes | 228/642 (35.5) | 166/359 (46.2) | 0.001 |
| Chronic kidney disease * | 300/651 (53.9) | 182/366 (49.7) | 0.199 |
| Prior pacemaker | 133/644 (20.7) | 73/363 (20.1) | 0.838 |
| CAD | 426/644 (66.1) | 235/366 (66.0) | 0.965 |
| Prior CABG | 96/644 (14.9) | 44/356 (12.4) | 0.266 |
| Prior PCI | 248/644 (38.5) | 134/356 (37.6) | 0.787 |
| Mitral valve insufficiency (>II°) | 22/633 (3.5) | 20/356 (5.6) | 0.109 |
| Prior valve replacement | 24/649 (3.7) | 16/364 (4.4) | 0.584 |
| LVEF (%) | 53.2 ± 12.9 | 51.7 ± 12.6 | 0.073 |
| NYHA | 0.498 | ||
| class III | 469/620 (75.6) | 256/347 (73.8) | |
| class IV | 53/620 (8.5) | 35/347 (10.1) | |
| NT-proBNP (pg/mL) | 2095 (871; 5573) | 2466 (1117; 6987) | 0.030 |
| Logistic EuroScore I (%) | 17.0 ± 11.8 | 17.9 ± 12.6 | 0.251 |
Legend: CAD, coronary artery disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; NT-proBNP, N-terminal pro brain natriuretic peptide; SD, standard deviation; IQR, interquartile range. * Defined as chronic kidney disease stage 2 or more with glomerular filtration rate (GFR) < 60mL/min.
Procedural and in-hospital outcomes.
| Rehabilitation ( | No Rehabilitation ( | ||
|---|---|---|---|
| Conversion to surgery | 4/650 (0.6) | 4/362 (1.1) | 0.467 |
| Stroke | 13/649 (2.0) | 12/362 (3.3) | 0.198 |
| PPI | 56/646 (8.7) | 21/364 (5.8) | 0.095 |
| Valve-in-valve | 24/651 (3.7) | 15/366 (4.1) | 0.743 |
| Hospitalization post-TAVI (days) | 7.0 (6.0; 9.0) | 6.0 (5.0; 8.0) | <0.001 |
| NT-proBNP (pg/mL) | 1777 (775; 3,722) | 1838 (879; 4,232) | 0.334 |
| Cardiac function at discharge † | |||
| LVEF (%) | 54.2 ± 11.1 | 52.5 ± 11.7 | 0.031 |
| Peak valve gradient (mmHg) | 11.8 ± 5.9 | 11.7 ± 5.5 | 0.865 |
| Aortic insufficiency | 0.230 | ||
| mild | 25/581 (4.3) | 9/321 (2.8) | |
| moderate/severe | 1/581 (0.2) | 2/321 (0.6) |
Legend: PPI, permanent pacemaker implantation; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro brain natriuretic peptide. SD, standard deviation; IQR, interquartile range. † Discharge from department where the TAVI was performed (discharge to home or rehabilitation unit).
Figure 2Overall survival during the first six months after TAVI. Kaplan-Meier survival curves for rehabilitation and control (no rehabilitation) groups.
Figure 3Variables associated with mortality at six months (multivariable adjusted). Legend: BMI, body mass index; renal impairment defined as glomerular filtration rate <60 mL/min; LVEF, left ventricular ejection fraction; TAVI, transcatheter aortic valve implantation; NT-pro BNP values were measured before TAVI.
Outcomes and cardiac function at six months.
| Rehabilitation Mean ± SD or Median (IQR) or proportion of patients (%) | No Rehabilitation Mean ± SD or Median (IQR) or proportion of patients (%) | ||
|---|---|---|---|
| All-cause mortality | 24/538 (4.5) | 30/289 (10.4) | 0.001 |
| CV death | 9/538 (1.7) | 8/289 (2.8) | 0.290 |
| Non-CV death | 7/538 (1.3) | 14/289 (4.8) | 0.002 |
| Unknown cause of death | 8/538 (1.5) | 8/289 (2.8) | 0.202 |
| Rehospitalization | 93/538 (17.3) | 61/289 (21.1) | 0.178 |
| Cardiac function | |||
| LVEF (%) | 55.0 ± 10.3 | 54.6 ± 10.6 | 0.636 |
| Peak valve gradient (mmHg) | 11.2 ± 5.7 | 11.3 ± 5.4 | 0.982 |
| Aortic insufficiency | 0.287 | ||
| mild | 17/414 (4.1) | 6/222 (2.7) | |
| moderate/severe | 1/414 (0.2) | 2/222 (0.9) | |
| NYHA | 0.105 | ||
| Class III | 158/392 (40.3) | 76/206 (36.9) | |
| Class IV | 4/392 (1.0) | 7/206 (3.4) | |
| NT-proBNP (pg/mL) | 849 (364, 1952) | 758 (381, 1951) | 0.778 |
Legend: LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; NT-proBNP, N-terminal pro brain natriuretic peptide; CV, cardiovascular; SD, Standard Deviation; IQR, Interquartile ranges.
Figure 4Survival during the first six months after TAVI for patients with cardiac vs. geriatric vs. no rehabilitation. Legend: Kaplan-Meier survival curves for geriatric rehabilitation, cardiac rehabilitation and control (no rehabilitation) groups.